The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC jointly recommended amidst an investigation into adverse events.

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

Due to an ongoing investigation of serious adverse events, it is recommended that the use of Ixchiq ® (chikungunya ... for Disease Control and Prevention (CDC). According to the Agencies, as ...

Recommendations for the use of chikungunya vaccine were recently discussed at a meeting of the Advisory Committee on Immunization Practices.

ACIP maintained ... to the use of IXCHIQ ® in persons aged ≥65 years. This precaution is a response to an ongoing investigation by the CDC of six cases of serious adverse events (SAEs ...

the ACIP voted to recommend a precaution related to the use of Ixchiq in patients aged 65 years and older due to an ongoing investigation by the CDC of 6 cases of serious adverse events ...

The ACIP also voted to recommend a precaution related to the use of IXCHIQ ® in persons aged ≥65 years. This precaution is a response to an ongoing investigation by the CDC of six cases of serious ...